PSMA: A Windfall for PET/CT Imaging
On the way to being included in clinical guidelines
Trial will be launched in 2017
“With this academically funded study we also want to give something back to the healthcare system and society. We have high expectations. Then we’ll see what happens.”Professor Klaus Kopka, MD, Head of Radiopharmaceutical Chemistry, DKFZ Heidelberg, Germany
68Ga-labelled PSMA-11 referenced herein is not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use.
Afshar-Oromieh, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol I 41, 11–20 (2014).
Schwenck, J. et al. Comparison of 68Galabelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol I 44, 92–101 (2016).
Perera, M. et al. Sensitivity, Specificity, and Predictors of Positive 68Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta.
- The statements by Siemens’ customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.